제2형 당뇨병 환자에서 Metformin/Dipeptidyl Peptidase-4 저해제 병용요법과 Metformin/Sulfonylurea 병용요법간의 효과에 대한 비교 연구
Comparative Effectiveness between Dipeptidylpeptidase-4 Inhibitors and Sulfonylureas in Combination with Metformin in Type 2 Diabetes Mellitus Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Treatment with sulfonylureas in combination with metformin improves glycemic control in type 2 diabetes mellitus (T2DM), but is associated with hypoglycemia and weight gain. This retrospective study aims to compare the effectiveness of dipeptidylpeptidase-4 (DPP-4) inhibitors and sulfonylureas as an add-on therapy to metformin in patients with T2DM. Methods: Data from medical records of 355 T2DM patients received therapy either DPP-4 inhibitors (DPP-4 inhibitor group) or sulfonylurea (SU group) in combination with metformin from 1 March 2009 to 30 September 2011 were retrospectively reviewed. Of total 355 patients, 231 patients were in DPP-4 inhibitor group and 124 patients were in SU group. Baseline Hemoglobin A1c (HbA1c) level in SU group was higher than DPP-4 inhibitor group with a statistically significant difference (8.6% vs. 7.8%). Comparative analysis between DPP-4 inhibitor group and SU group was performed for HbA1c values, amounts of HbA1c changes, and rates of HbA1c changes from baseline at 6-month intervals and incidence rates of major cardiocerebral events. Results: SU group showed larger HbA1c changes in both amounts and rates compared to DPP-4 inhibitor group, although statistical significance was not found in all study periods. Proportions of patients with stable HbA1c <6.5% or 7% were significantly higher in DPP-4 inhibitor group than SU group (<6.5%: 30.4% vs. 13.4%, <7%: 72.3% vs. 41.2%). Time to achieve stable HbA1c <6.5% was not significantly different, but time to achieve stable HbA1c <7% was shorter in DPP4 inhibitor group than SU group with a significant difference. The incidence rate of cardiocerebral events in group of patients with or without previous events was 1.7%, not significantly lower than that in DPP-4 inhibitor group (4.0%). For newly encountered cardiocerebral events during the treatment, incidence rates of two groups did not differ significantly. Conclusion: DPP-4 inhibitors were as effective as sulfonylureas in achieving the HbA1c goal of less than 6.5% or 7% and cardiocerebral event rates did not differ between the two drugs.
Abstract
Objective: Treatment with sulfonylureas in combination with metformin improves glycemic control in type 2 diabetes mellitus (T2DM), but is associated with hypoglycemia and weight gain. This retrospective study aims to compare the effectiveness of dipeptidylpeptidase-4 (DPP-4) inhibitors and sulfonylureas as an add-on therapy to metformin in patients with T2DM. Methods: Data from medical records of 355 T2DM patients received therapy either DPP-4 inhibitors (DPP-4 inhibitor group) or sulfonylurea (SU group) in combination with metformin from 1 March 2009 to 30 September 2011 were retrospectively reviewed. Of total 355 patients, 231 patients were in DPP-4 inhibitor group and 124 patients were in SU group. Baseline Hemoglobin A1c (HbA1c) level in SU group was higher than DPP-4 inhibitor group with a statistically significant difference (8.6% vs. 7.8%). Comparative analysis between DPP-4 inhibitor group and SU group was performed for HbA1c values, amounts of HbA1c changes, and rates of HbA1c changes from baseline at 6-month intervals and incidence rates of major cardiocerebral events. Results: SU group showed larger HbA1c changes in both amounts and rates compared to DPP-4 inhibitor group, although statistical significance was not found in all study periods. Proportions of patients with stable HbA1c <6.5% or 7% were significantly higher in DPP-4 inhibitor group than SU group (<6.5%: 30.4% vs. 13.4%, <7%: 72.3% vs. 41.2%). Time to achieve stable HbA1c <6.5% was not significantly different, but time to achieve stable HbA1c <7% was shorter in DPP4 inhibitor group than SU group with a significant difference. The incidence rate of cardiocerebral events in group of patients with or without previous events was 1.7%, not significantly lower than that in DPP-4 inhibitor group (4.0%). For newly encountered cardiocerebral events during the treatment, incidence rates of two groups did not differ significantly. Conclusion: DPP-4 inhibitors were as effective as sulfonylureas in achieving the HbA1c goal of less than 6.5% or 7% and cardiocerebral event rates did not differ between the two drugs.
참고문헌 (20)
- Sarwar N., "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies", Lancet, 375(9733), pp.2215~2222 (2010)
- Morrish, NJ., "Mortality and causes of death in the WHO multinational study of vascular disease in diabetes", Diabetologia, 44(Suppl. 2), pp.S14~S21 (2001)
- Stratton IM., "Association of glycaemia with macrovascular complications of type 2 diabetes(UKPDS 35) : prospective observational study", BMJ, 32(7258), pp.405~412 (2000)
- Filozof C., "A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone : a 52-week, randomized study", Diabet Med, 27(3), pp.318~326 (2010)
- Seck T., "Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin : a 2-year study", Int J Clin Pract, 64(5), pp.562~576 (2010)
- Gallwitz B., "Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years", Int J Clin Pract, 67(4), pp.317~321 (2013)
- Karagiannis T., "Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis", BMJ, 344, pp.e1369~e1383 (2012)
- Zhang Y., "Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials", Diabetes Metab Res Rev, 30(3), pp.241~256 (2014)
- Rathmann W., "Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas : a primary care database analysis", Diabetes Obes Metab, 15(1), pp.55~61 (2013)
- Patil HR., "Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus", Am J Cardiol, 110(6), pp.826~833 (2012)
- Green JB., "Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin(TESCO)in patients with type 2 diabetes and established cardiovascular disease", Am Heart J, 166(6), pp.983~989 (2013)
- Hirst JA., "Estimating the effect of sulfonylurea on HbA1c in diabetes : a systematic review and meta-analysis", Diabetologia, 56(5), pp.973~984 (2013)
- Sherifali D., "The effect of oral antidiabetic agents on A1C levels : a systematic review and meta-analysis", Diabetes Care, 33(8), pp.1859~1864 (2010)
- Park H., "Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes : meta-analysis", Ann Pharmacother, 46(11), pp.1453~1469 (2012)
- DeFronzo RA., "Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies : a meta-analysis of randomized clinical trials", Diabet Med, 27(3), pp.309~317 (2010)
- Bloomgarden ZT., "Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy", Diabetes Care, 29(9), pp.2137~2139 (2006)
- Esposito K., "Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes : meta-analysis of randomized controlled trials", Diabetes Obes Metab, 13(7), pp.594~603 (2011)
- Monami M., "Cardiovascular safety of sulfonylureas : a meta-analysis of randomized clinical trials", Diabetes Obes Metab, 15(10), pp.938~953 (2013)
- Morgan CL., "Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors : association with major adverse cardiovascular events and all-cause mortality", Diabetes Obes Metab, 16(10), pp.977~983 (2014)
- Yu OH., ". The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death" (2015), Can J Diabetes